Australia's most trusted
source of pharma news
Posted 16 October 2025 AM
Two new drugs are on their way to Australia, along with new indications for two more, including one on the World Health Organisation's (WHO) list of essential medicines.
Viatris has received two orphan drug designations for pretomanid, a tuberculosis treatment that is marketed overseas under the brand name Dovprela. One indication is in combination with bedaquiline, linezolid, and moxifloxacin for the treatment of adults with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to rifampicin, with or without resistance to isoniazid, while the second leaves out moxifloxacin to treat disease that is also resistant to fluoroequinolones such as moxifloxacin.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.